PS
PTGX icon

Principal Securities’s Protagonist Therapeutics PTGX Stock Holding History

Principal Securities’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32
Closed -$2.13K – 2976
2025
Q3 		$2.13K Sell
32
-4
-11% -$227 ﹤0.01% 3213
2025
Q2 		$1.99K Buy
36
+24
+200% +$1.15K ﹤0.01% 3149
2025
Q1 		$463 Hold
12
– – ﹤0.01% 3368
2024
Q4 		$463 Sell
12
-3
-20% -$131 ﹤0.01% 3363
2024
Q3 		$675 Buy
15
+9
+150% +$364 ﹤0.01% 3218
2024
Q2 		$208 Hold
6
– – ﹤0.01% 3308
2024
Q1 		$174 Hold
6
– – ﹤0.01% 3253
2023
Q4 		$138 Buy
+6
New +$105 ﹤0.01% 3168

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Principal Securities's PTGX Position: Q4 2025 in Review

Principal Securities sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 32 shares — an estimated $2.13K sold.

Principal Securities first reported a position in PTGX in Q4 2023 and held it in 8 quarters. The position peaked at $2.13K in Q3 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Principal Securities reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 32 Protagonist Therapeutics shares in Q4 2025, an estimated $2.13K.
  • Principal Securities first reported a position in Protagonist Therapeutics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Protagonist Therapeutics position peaked at $2.13K in Q3 2025.
  • 313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.